Persistent revertants have been generated from NIH 3T3 cells transformed by an activated human Ha-ras gene after short-term gamma interferon treatment in the presence of the cardiac aminoglycoside ouabain. Normal fibroblastlike morphology and anchorage dependence are restored in revertants. Tumorigenicity in nude mice is abolished. The revertants continue to express high steady-state levels of the ras oncogene. Partial retransformation of reverted cells is induced after 5-azacytidine treatment or after infection with retrovirus vectors carrying the v-abl, v-fes, v-myc, or v-src oncogene. The revertants resist the transforming activities of the v-Ha-ras and v-mos oncogenes.
Interferons (IFNs) exhibit growth-inhibitory and antitumoral action on a number of malignant cells (for review, see reference 21) . We are interested in the effects of IFNs on the expression of neoplastic transformation triggered by cellular or viral oncogenes. Mouse IFN inhibited the development of transformed foci in NIH 3T3 cells transfected with the viral Harvey murine sarcoma virus ras and Moloney murine sarcoma virus mos oncogenes (25) . Reversion to a more normal phenotype has been described for IFN-treated cells harboring either the v-mos oncogene (29) (30) (31) , the v-Ki-ras oncogene (7) , a long terminal repeat-activated H-ras oncogene (24, 26) , or the long terminal repeat-controlled c-myc oncogene (30) . When transformed cells were treated with alpha-beta IFN (IFN-a/3) or IFN--y for a short time, reversible phenotypic normalization occurred owing to transcriptional inhibition of oncogene expression (23, 26, 30) . In contrast, long-term IFN-ot treatment resulted in the persistent reversion of oncogene-transformed cells, caused by a posttranslational inhibition of oncogene action (26, 31) .
Here we describe the isolation of persistent IFN-y revertants derived from EJ-ras-transformed NIH 3T3 cells (NIHpEJ c13). In contrast to previous protocols, transformed NIH 3T3 cells were treated with recombinant murine IFN--y for a short time in combination with a selection procedure which served to eliminate transformed cells. Selection against transformed cells was accomplished by treatment with the cardiac aminoglycoside ouabain. Ouabain selectively kills ras-transformed cells, whereas normal cells are relatively resistant to this treatment (19, 28 tion and of the v-abl, v-fes, v-myc, or v-src oncogene by retrovirus infection. The transforming activity of oncogenes transferred into IFN revertants was determined by monitoring foci of morphologically transformed cells and of colonies in semisolid-agar medium. Expression of the abl, fes, myc, and src oncogenes caused morphological transformation of the IFN-4 and IFN-10 cells (data not shown). Those cells were able to form colonies in soft-agar medium (Table 3 ). In contrast, the v-Ha-ras and v-mos oncogenes failed to induce foci and soft-agar colony formation (Table 3 ). treatment suggests that the cytokine has had a direct effect on the expression of a gene(s) which encodes effector molecules necessary for cellular transformation. The simultaneous ouabain selection resulted in the rapid elimination of transformed cells and enrichment of revertants. Phenotypic reversion of NIHpEJ c13 cells was not due to the loss or transcriptional inactivation of the EJ-ras gene, since the revertants continued to express high levels of ras mRNA as well as of the ras gene product p21.
The loss of the neoplastic phenotype in spite of the continued expression of transforming ras genes has been described for other cells besides the flat revertants isolated after IFN-ot/1 treatment (26) . Derivatives of ras-transformed cells were isolated after mutagenesis (17, 19, 34) , after fusion with normal diploid cells (5, 8, 9) , and after transfection with untreated or 5-azacytidine-treated cells as described in Table 1 , footnote a. The values represent the average cloning efficiency determined in three independent experiments.
identical cellular pathway? Furthermore, does the sensitivity to src-induced transformation indicate the existence of a kinase oncogene-stimulated signalling pathway that is independent of ras? The ouabain-selected flat revertants described by Noda et al. (18) were both resistant to ras and src oncogenes but permissive to v-mos transformation. Evidence from analysis of revertants of independent origin (10, 17, 35) and of somatic cell hybrids (11) suggests that ras and src proteins may be components of the same cellular pathway triggering neoplastic transformation. Neoplastic transformation by v-src was blocked by microinjection of a specific antibody capable of neutralizing the endogenous ras proteins (32) . The pattern of resistance to oncogenic transformation found in IFN-c/1 revertants (26) is in accordance with a common signalling pathway for src and ras gene products. However, the resistance to ras-induced transformation and sensitivity to src-induced transformation described in this report suggests that deregulated tyrosine 
